Glaucoma is the leading cause of irreversible blindness worldwide, with an estimated 70 million people affected by the condition. With the aging population, it is expected that the prevalence of glaucoma will continue to increase, resulting in an estimated 80 million people with glaucoma by 2020. Recent advances in imaging have facilitated earlier glaucoma diagnosis and subsequent timely initiation of therapy, potentially reducing irreversible blindness and loss of quality of life. Therapies for glaucoma either increase outflow or decrease production of aqueous humor to reduce intraocular pressure (IOP), but IOP must be tightly controlled to provide optimal patient outcomes. In this activity, leading clinicians will evaluate clinical evidence for the safety and efficacy of established, new, and emerging classes of glaucoma medications, as well as discuss their mechanisms of action for the effective management of IOP.
An FDA advisory committee voted unanimously that Spark Therapeutics’ Luxturna gene therapy for retinal dystrophy has an overall favorable benefit-risk profile.
Sixteen members of the Cellular, Tissue, and Gene Therapies Advisory Committee voted yes and zero voted no, with zero abstentions, on the following question: Considering the efficacy and safety information provided in the briefing document, as well as the presentations and discussions during the AC meeting, does voretigene neparvovec have an overall favorable benefit-risk profile for the treatment of patients with vision loss due to confirmed biallelic RPE65 mutation-associated retinal dystrophy?
Dr. Paul Singh highlighted the diagnostic aspect of SLT during the 2017 Combined Ophthalmic Symposium in Austin, Texas. When asked if there was still a role for trabeculoplasty in managing glaucoma, Dr. Singh emphasized the many options now available for treating glaucoma patients in a customized fashion. He went on to note that in his practice, he has asked himself if SLT may provide some knowledge
as to where the resistance in out ow may be: “when SLT works, could it be that the trabecular meshwork is the main area of resistance... or when it doesn’t work does this tell us that maybe it is in the Schlemm’s canal or distal to it.”
In his opinion, SLT may help give a better understanding preoperatively of where the resistance lies.
For many years, the gold standard for surgical treatment of glaucoma has been trabeculectomy. While effective in reducing intraocular pressure (IOP), trabeculectomy comes with its share of complications, including vision-threatening events such as endophthalmitis or choroidal hemorrhage. The introduction of minimally invasive glaucoma surgery (MIGS) has revolutionized the glaucoma treatment paradigm by allowing for earlier surgical intervention.
I invite you to attend the ICO’s World Ophthalmology Roundtable on Leadership Development (WORLD) on Saturday, 11 November 2017 from 12:00–13:45 in the Louisiana Ballroom at the Loews Hotel, New Orleans. A light lunch will be served at 11:30.
Purpose: Ab interno trabeculectomy (AIT) with the Trabectome has been shown to reduce intraocular pressure (IOP) in eyes with pseudoexfoliation (PEX) glaucoma. Here, we examined the change of IOP fluctuations before and after only AIT or AIT with cataract surgery in PEX patients using the contact lens sensor Triggerfish®.
During the procedure the iTrack™ is threaded through the canal with micro-forceps, providing real-time tactile feedback of the health and patency of the canal. As the iTrack™ is withdrawn, the precisely controlled delivery of Healon/Healon GV separates the compressed tissue planes of the trabecular meshwork, and also triggers the withdrawal of any herniated inner wall tissue from the collector channels. A standout feature of the iTrack™ is its illuminated tip, which allows you to continually monitor its location during canal circumnavigation – offering peace of mind that the iTrack™ is safely in the canal.
When it comes to MIGS, a key advantage of the iTrack™ microcatheter is that it provides real-time tactile feedback of the health and patency of Schlemm’s canal. During the ABiC™ procedure, the iTrack™ is threaded through the canal with micro-forceps. As the iTrack™ is withdrawn, the precisely controlled delivery of Healon/Healon GV separates the compressed tissue planes of the trabecular meshwork, and also triggers the withdrawal of any herniated inner wall tissue from the collector channels.
“The iTrack enables you to feel if the canal is tight, grainy, or completely open. It also features a rounded, atraumatic tip, as well as a lubricious coating, which enables it to be maneuvered past tight areas of the canal, or areas that are partially obstructed. As an added benefit, an illuminated tip allows you to continually monitor its location during canal circumnavigation.”
Mark J. Gallardo, MD El Paso Eye Surgeons, Texas
Abstract: Over the last decade several novel surgical treatment options and devices for glaucoma have been developed. All these developments aim to cause as little trauma as possible to the eye, to safely, effectively, and sustainably reduce intraocular pressure (IOP), to produce reproducible results, and to be easy to adopt. The term “micro-invasive glaucoma surgery (MIGS)” was used for summarizing all these procedures. Currently MIGS is gaining more and more interest and popularity. The possible reduction of the number of glaucoma medications, the ab interno approach without damaging the conjunctival tissue, and the probably safer procedures compared to incisional surgical methods may explain the increased interest in MIGS. The use of glaucoma drainage implants for lowering IOP in difficult-to-treat patients has been established for a long time, however, a variety of new glaucoma micro-stents are being manufactured by using various materials and are available to increase aqueous outflow via different pathways. This review summarizes published results of randomized clinical studies and extensive case report series on these devices, including Schlemm’s canal stents (iStent®, iStent® inject, Hydrus), suprachoroidal stents (CyPass®, iStent® Supra), and subconjunctival stents (XEN). The article summarizes the findings of published material on efficacy and safety for each of these approaches.
Keywords: glaucoma, micro-invasive glaucoma surgery, MIGS, iStent, iStent inject, CyPass, Hydrus, XEN
Daniel Edward Robert Beck,1 Karim El-Assal,1 Ken McGarry,2 Nicholas Kloster Wride1
1Sunderland Eye Infirmary, 2Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland, UK
We read with interest the article by Negrete et al.1 A recent study performed at our unit found similar results on conducting a review of tolerance to preservative-free latanoprost (Monopost) in patients who were unable to tolerate preserved formulae, and we would like to take the opportunity to share the results with you.
The long-term effects of the FDA Reauthorization Act of 2017 — signed into law by President of the USA - Donald J. Trump on Monday — may include savings in drug-related Medicare expenses due to increased competition encouraged by the FDA by fast-tracking generic competitor approvals, according to an expert.
Сообщаем Вам, что 16-17 ноября 2017 года состоится юбилейная научная конференция офтальмологов, посвященная 110-летию образования медицинской службы завода «Адмиралтейские верфи»
Sarwat Salim, MD, sits down with Steven Vold, MD, to discuss how to manage vitreous in the anterior chamber of a glaucoma patient. Dr. Salim shares pearls for determining treatment strategy and explains whether a trabeculectomy or tube shunt procedure is more appropriate
Congratulations on your induction into the ASCRS Hall of Fame!
I feel very humbled and honored. To be commemorated in this way is a huge deal and totally unexpected. When I accepted the honor, I told the audience that the very fact they had recognized me was symbolic of their commitment to eliminate needless blindness in the world.
Сайт основан 20 декабря 2000 года
Авторские права на дизайн и всю информацию веб-сайта www.eyenews.ru (www.glaucomanews.ru www.corneanews.ru, www.cataractanews.ruwww.retinanews.ru www.айньюс.рф www.hrtclubrussia.ru), а также на подбор и расположение материалов принадлежат учредителю и редакции вышеуказаных порталов. Использование материалов сайтов разрешено только с письменного разрешения учредителя и редакции вышеуказанных сайтов. Воспроизведение фотографий, статей и новостей, абстрактов и прочего контента любым способом без письменного разрешения запрещено и влечет ответственность, предусмотренную законодательством о защите авторских прав. Запрещается автоматизированное извлечение информации сайта любыми сервисами без официального разрешения учредителя либо редакции сайтов. При цитировании материалов ссылка наwww.eyenews.ru и другие вышеуказанные сайты обязательна.